VJHemOnc Podcast

MRD assessment in AML: incorporation into clinical practice

Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable...

The post MRD assessment in AML: incorporation into clinical practice appeared first on VJHemOnc.

Myeloma management in the COVID-19 era

The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians...

The post Myeloma management in the COVID-19 era appeared first on VJHemOnc.

CAR-T in the CLL space

Novel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients...

The post CAR-T in the CLL space appeared first on VJHemOnc.

CAR T-cell therapy & multiple myeloma: past, present & future

CAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable...

The post CAR T-cell therapy & multiple myeloma: past, present & future appeared first on VJHemOnc.

Harnessing the tumor microenvironment in lymphoma therapy

A deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into...

The post Harnessing the tumor microenvironment in lymphoma therapy appeared first on VJHemOnc.

Induction therapy in myeloma: an ever-changing paradigm

In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only been possible with the use of high-dose therapy plus autologous stem cell transplantation. Novel agents are changing the treatment landscape, with combinations of daratumumab, dexamethasone, thalidomide, bortezomib and lenalidomide increasing the rates of complete remission and partial response compared to VAD.

In this podcast, the endless possible combinations are discussed by Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France. Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Mohty gives us his insight into induction therapy and also where we may be going next.

Precision epigenetic therapy for B-cell lymphoma

Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus, a continued need exists for the development of innovative approaches and therapies. Epigenetic dysregulation may drive and/or promote tumorigenesis in various malignancies and is prevalent in both B-cell and T-cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of patients with hematological malignancies. This podcast features Ari Melnick, MD, of the Weill Cornell Medical College, New York, NY. The footage included is from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Acute leukemia: pushing boundaries in disease management

This is an exciting time in the acute leukemia field, with advances in both the treatment landscape and the pathology of the disease. This podcast features a recent discussion amongst acute leukemia experts from the International Workshop on Acute Leukemias (iwAL) 2019 conference held in Barcelona, Spain. In this podcast, Noelle Frey, MD , University of Pennsylvania, Philadelphia, PA; Bianca Santomasso, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY; and Wendy Stock, MD, of the University of Chicago Medicine, Chicago, IL, discuss a vast range of topics, including the improvement of patient outcomes, the use of CAR T-cell therapy and the importance of MRD in prognostics.

iwAL 2019: looking to the future of acute leukemia therapy

The treatment landscape of acute myeloid and lymphoblastic leukemia continues to evolve with the addition of novel therapies and methods to monitor disease. One such example is the use of measurable residual disease (MRD) status to plan treatment, determine disease prognosis, and compare treatment efficacy. In terms of novel treatments, CAR T-cell therapy has proven promising for treating acute lymphoblastic leukemia, and will continue to be a key focus of research in the near future. In this podcast, Alan Burnett, MD, PhD, of Cardiff University, Cardiff, UK; Andrew Wei, MBBS, PhD, FRACP, FRCPA, of Monash University, Victoria, Australia; and Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discuss the future of acute leukemia therapy at the International Workshop on Acute Leukemias (iwAL) 2019 meeting held in Barcelona, Spain.

CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma

Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a discussion with world-class lymphoma experts: Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, and Caron Jacobson, MD, from the Dana-Farber Cancer Institute, Boston, MA, on key updates from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. The group explores the use of CAR T-cell therapy, considering the hurdles and benefits, and discusses the realm of precision medicine in this field.